Zobrazeno 81 - 90
of 235
pro vyhledávání: '"Manal F. Abdelmalek"'
Autor:
Stephen J. Rossi, Mary E. Rinella, Mark J. Jaros, Alex M. DePaoli, Marcelo Kugelmas, Stephen A. Harrison, Manal F. Abdelmalek, Hays Arnold, James F. Trotter, Mustafa R. Bashir, ing L, Angelo H. Paredes, Rohit Loomba
Publikováno v:
The Lancet. 391:1174-1185
Non-alcoholic steatohepatitis is a chronic liver disease characterised by the presence of hepatic steatosis, inflammation, and hepatocellular injury, for which no Food and Drug Administration (FDA)-approved treatment exists. FGF19 is a hormone that r
Autor:
S. Megnien, Mohammad S. Siddiqui, Laurent Castera, Katherine Greene, Veronica Miller, Elmer Schabel, David E. Kleiner, Manal F. Abdelmalek, Arun J. Sanyal, Stephen A. Harrison, Scott L. Friedman, Quentin M. Anstee, Vlad Ratziu, Pierre Bedossa, Brent A. Neuschwander-Tetri, Lara Dimick-Santos
Publikováno v:
Hepatology (Baltimore, Md.)
Nonalcoholic steatohepatitis (NASH) is an important cause of liver-related morbidity and mortality. There are no approved therapies, and the results of clinical trials have been difficult to compare due to inconsistent definitions of relevant disease
Autor:
Kris V. Kowdley, Mark L. Van Natta, Arun J. Sanyal, James Tonascia, Edward Doo, Raj Vuppalanchi, Mohammad S. Siddiqui, David E. Kleiner, Manal F. Abdelmalek, Rohit Loomba, Danielle Brandman, Erin Hallinan, Brent A. Neuschwander-Tetri, Srinivas Dasarathy, Naga Chalasani
Publikováno v:
Hepatology. 67:134-144
Vibration-controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively. However, prior vibration-controlled
Autor:
Manal F. Abdelmalek
Publikováno v:
Nature Reviews. Gastroenterology & Hepatology
In 2020, there have been substantial advances in nonalcoholic fatty liver disease mechanisms, diagnostics and treatment. Key developments include the identification of a cellular and tissue signature to provide new insights into pathophysiology, adva
Autor:
Laura A. Wilson, Nathan M. Bass, Ayako Suzuki, Ryan M. Gill, Norah A. Terrault, Marcelle I. Cedars, Manal F. Abdelmalek, Monika Sarkar, Katherine P. Yates
Publikováno v:
Clin Gastroenterol Hepatol
BACKGROUND: Higher testosterone contributes to imaging-confirmed nonalcoholic fatty liver disease (NAFLD) in women, but whether testosterone influences their disease severity is unknown. METHODS: The association of free testosterone (free T) with non
Autor:
Kara Wegermann, Ayako Suzuki, Alisha M. Mavis, Manal F. Abdelmalek, Anna Mae Diehl, Cynthia A. Moylan
Publikováno v:
Hepatology. 73:1625-1625
We appreciate de Zegher and Ibanez calling attention to the association between non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). As de Zegher and Ibanez rightly point out, NAFLD can occur in children and adolescents w
Autor:
Manal F. Abdelmalek, Cynthia A. Moylan
Publikováno v:
Hepatology. 68:1646-1648
Autor:
David E. Bernstein, Lewis Teperman, Cen Wu, Rakhi Maiwall, Aijaz Ahmed, Ajay Duseja, Keyur Patel, Sanjaya K. Satapathy, Satish Kedia, Puneet Puri, Kalyan Ram Bhamidimarri, Paul J. Thuluvath, Prasun K. Jalal, Vincent Wai-Sun Wong, Ravi Ravinuthala, Uchenna Agbim, Ashwani K. Singal, Yu Jiang, Guruprasad P. Aithal, Manal F. Abdelmalek, Benedict Maliakkal
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation SocietyReferences. 26(1)
Morbid obesity is considered a relative contraindication for liver transplantation (LT). We investigated if body mass index (BMI; lean versus obese) is a risk factor for post-LT graft and overall survival in nonalcoholic steatohepatitis (NASH) and no
Autor:
Bill Tan, Eduardo B. Martins, Andrea D. Coviello, Naim Alkhouri, Ralph W. Charlton, Manal F. Abdelmalek
Publikováno v:
Diabetes. 68
Background: The treatment landscape of nonalcoholic steatohepatitis (NASH) is changing rapidly; drug safety is key as most patients will need long-term treatment. Cenicriviroc (CVC) is an oral antagonist of C-C chemokine receptors 2/5 in Phase 3 deve
Autor:
Ralph W. Charlton, Manal F. Abdelmalek, Eduardo B. Martins, Andrea D. Coviello, Henrik Landgren, Naim Alkhouri
Publikováno v:
Diabetes. 68
Background: Nonalcoholic steatohepatitis (NASH) is considered the hepatic manifestation of type 2 diabetes and can progress to advanced fibrosis (AF), associated with significant increase in morbidity and mortality. CVC is an oral C-C chemokine recep